Aquatic Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Aquatic Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$271K	Sell	12,656 -181,847	-93%	-$2.79M	0.01%	942
2026 Q1	$2.7M	Buy	194,503 +71,539	+58%	+$1.14M	0.08%	310
2025 Q4	$2M	Sell	122,964 -15,532	-11%	-$253K	0.06%	374
2025 Q3	$2.07M	Buy	138,496 +30,306	+28%	+$369K	0.04%	486
2025 Q2	$1.26M	Buy	+108,190	New	+$983K	0.03%	589
2023 Q2	–	Sell	-6,500	Closed	-$57K	–	1285
2023 Q1	$57K	Buy	6,500 +2,000	+44%	+$17.6K	﹤0.01%	863
2022 Q4	$34K	Buy	4,500 +3,500	+350%	+$27.2K	﹤0.01%	1083
2022 Q3	$7K	Sell	1,000 -100	-9%	-$942	﹤0.01%	1070
2022 Q2	$9K	Buy	+1,100	New	+$9.67K	﹤0.01%	978

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aquatic Capital Management's ADPT Position: Q2 2026 in Review

Aquatic Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 93% in Q2 2026, selling an estimated $2.79M and leaving 12,656 shares worth $271K. The position accounts for 0.01% of the portfolio, ranked #942.

Aquatic Capital Management first reported a position in ADPT in Q2 2022 and has held it in 9 quarters since. The position peaked at $2.7M in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Aquatic Capital Management held 12,656 shares of Adaptive Biotechnologies worth $271K as of Q2 2026.
Aquatic Capital Management sold 181,847 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.79M.
Adaptive Biotechnologies made up 0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #942 holding.
Aquatic Capital Management first reported a position in Adaptive Biotechnologies in Q2 2022 and has held it in 9 quarters since.
Aquatic Capital Management's Adaptive Biotechnologies position peaked at $2.7M in Q1 2026.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.